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Abstract 
 
The GATE 6.1 Monte Carlo simulation platform based on the GEANT4 toolkit is in constant 15 
improvement for dosimetric calculations. Here, we explore its use for calculating internal absorbed 
dose distribution in mice for the treatment of malignant melanoma after injection of a new specific 
radiopharmaceutical labeled with iodine 131. We estimate the dosimetric accuracy of GATE 6.1, by 
calculating first S values and by comparing them and absorbed doses to organswith EGSnrc for a 
digital mouse phantom and a CT scan based mouse phantom. 20 
 
1. Introduction 
 
GATE 6.1 [Jan et al 2004, Jan et al 2011] is a Monte Carlo simulation platform which makes use of 
GEANT4 version 9.4 [Agostinelli et al 1993, GEANT4 2010]. Through a user-friendly interface 25 
without the complexity of GEANT4, GATE offers now a diversity of tools dedicated to radiotherapy: 
geometry and source modeling, time dependence management, use of recent GEANT4 models and 
processes. Nevertheless, GATE hasn't been used widespread for nuclear medicine therapy but much 
more in the field of small animal nuclear medicine imaging and quantification. In a previous paper, we 
have validated GATE making use of GEANT4 version 9.4 Standard Electromagnetic Physics Package  30 
for the production of accurate dose distributions using monoenergetic electrons from 50 keV to 20 
MeV in agreement with EGSnrc or MCNP4C [Maigne et al 2011]. Here, we explore its use for 
targeted radiotherapy using 
131
I by computing S values on digital and CT scan based mouse phantoms 
and comparing our results to EGSnrc simulations. Then, these results were applied in a preclinical 
study involving a new radiolabeled melanin-localizing benzamide, named ICF01012, selected to treat 35 
the malignant melanoma [Chezal et al 2008]. 
131
I-labeled ICF01012 may be effective for therapeutic 
targeting of melanin-positive melanoma. Before testing this radiopharmaceutical on human, we 
performed a dosimetric study in mice using the MIRD methodology [Loevinger et al 1991]. S values 
computed with GATE were combined with pharmacokinetics extracted from [
125
I]-ICF01012 
biodistribution [Chezal et al 2008, Bonnet Duquennoy et al 2009]. 40 
 
2. Materials and Methods 
 
 2.1. Monte Carlo codes 
 45 
  2.1.1. GATE 
 
2 
 
The present work was performed with version 6.1 of the GATE generic Monte Carlo platform. This 
version of GATE makes use of GEANT4 version 9.4. The GEANT4 Standard Electromagnetic 
Physics Package which describes electron and photon interactions between 990 eV and 100 TeV, was 50 
used in all simulations, taking into account electron impact ionisation, multiple scattering, and 
bremsstrahlung generation. We implemented these physics processes (Physics List) according to the 
ElectroMagnetic Physics List Standard option 3which is designed by the GEANT4 collaboration for 
applications requiring higher accuracy for electrons, hadrons and ions tracking without magnetic 
fields. The production threshold was set to 2 µm for electrons, positrons and photons. 55 
 
  2.1.2. EGSnrc 
 
Simulations were performed using the EGSnrc C++ class library egspp [Kawrakow et al 2009]. We 
applied the PRESTA II electron-step algorithm and the EXACT boundary crossing algorithm. The 60 
electron and the photon tracking cuts, respectively ECUT and PCUT, were set to 521 keV and 10 keV. 
Statistical uncertainties were always kept under 2%. 
 
 2.2. Monte Carlo simulations set up 
 65 
  2.2.1. Digital mouse phantom 
 
The phantom was the MOBY whole-body mouse representing a 33g, normal 16-week-old male 
C57BL6 mouse [Segars et al 2004]. The phantom was realized as a three-dimensional, rectangular 
array of 128×128×450 cubic voxels of 0.25×0.25×0.25 mm
3
. It was enhanced by the addition of a 70 
spherical structure of 10 mm in diameter representing the melanoma tumor, located on the right side of 
the mouse and by the addition of two spherical structure of 3.4 mm for both eyes. Densities of four 
materials were defined : soft tissue (1.0 g.cm
-3
), lung (0.3 g.cm
-3
), bone (1.92 g.cm
-3
) and air (1.25 
mg.cm
-3
). Mass of organs of interest were chosen as reported in Table 1. 
 75 
  2.2.2. CT scan based phantom 
 
CT scans of C57BL6 mouse were obtained using an Explore CT 120 MicroCT of General Electrics. A 
modified Feldkamp's filtered back-projection algorithm was used to reconstruct a 3D volume with 
875×875×1041 voxels at an isotropic voxel size of 98.85 μm. We chose CT images 12 hours after 80 
injection of [
131
I]-ICF01012. The ISOgray treatment planning systems was then used to contour organs 
of interest in the reconstructed CT mouse volume. Tumor, eyes, bones, lung, kidneys, liver and thyroid 
were contoured. We applied the same densities and atomic compositions for organs as chosen for the 
MOBY phantom. The mass of organs of interest are listed in Table 1. 
 85 
Table 1 : Masses of organs of the mouse phantoms considered. 
Organs 
Mass MOBY 
phantom (g) 
Mass CT scan phantom 
(g) 
Melanoma 0.20 0.28 
Thyroid 0.0005 0.0003 
Eyes 0.015 0.014 
Liver 0.59 0.58 
Kidneys 0.30 0.18 
Lungs 0.15 0.12 
 
  2.2.3. S values computations 
3 
 
131
I decay was simulated by isotropically emitting electrons and photons in organs according to the 
131
I 
electron energy spectrum and gamma rays
1
. A total of 25.10
6
 particles per organ were simulated to 90 
produce dose distributions and compute S values for each organ in the phantom. The statistical relative 
uncertainty was below 0.2%. 
 
 2.3. Quantification of the biodistribution 
 95 
The goal of the quantification of the distribution is to estimate the cumulated activity of [
131
I]-
ICF01012 for each organ in order to compute absorbed. In this study, the cumulated activity was 
extracted from [
125
I]-ICF01012 pharmacokinetics. 
 
  2.3.1. Data acquisition of iodine labeled benzamide 100 
 
125
I-labeled ICF01012 radiopharmaceutical biodistribution was tested on ten male black mice C57BL6 
of approximately 24 grams (Iffa-Creed, France) bearing melanoma tumors without metastases. The 
quantification of the activity expressed in kBq/g was carried out using a detector-imaging AMBIS 
4000 (Scanalytics, CSPI, San Diego, CA). Seventeen days before administration of the [
125
I]-105 
ICF01012, melanoma cells were introduced by subcutaneous injection on the side of each mouse. 
Radiopharmaceutical activity was 1.7 MBq. Two mice were euthanized at 1 hour, 6 hour, 24 hour, 5 
days, and 8 days after intravenous administration of [
125
I]-ICF01012. Sagittal sections of 40 μm were 
used for measurements of the activity in the following organs from 2 to 20 slices: tumor, eyes, liver, 
lungs, kidneys and thyroid. 110 
 
  2.3.2. Effective periods and cumulated activity calculations 
 
From [
125
I]-ICF01012 biodistributions, we determined the initial activity of the radiopharmaceutical by 
a mono-exponential fit. The effective period of [
131
I]-ICF01012 was calculated by taking into account 115 
the same biological period as [
125
I]-ICF01012. Then, the cumulated activity of [
131
I]-ICF01012 was 
computed for a therapeutic activity of 37 MBq. Table 2 shows the quantities determined for different 
organs. 
 
Table 2 : 
131
I biological period (h), 
131
I effective period (h), 
125
I initial activity (Bq/kg) and 
131
I cumulative 120 
activity (Bq.s/kg) for melanoma, thyroid, eyes, liver, kidneys and lungs. 
Organs 
131
I biological 
period 
(h) 
131
I effective period 
(h) 
125
I initial activity 
(Bq/kg) 
131
I cumulative activity 
(Bq.s/kg) 
Melanoma 150.6 84.5 3.61x10
8
 3.44x10
15
 
Thyroid 101.9 66.6 7.49x10
8
 5.63x10
15
 
Eyes 273.2 112.9 4.24x10
8
 5.40x10
15
 
Liver 7.6 7.6 1.77x10
8
 1.52x10
14
 
Kidneys 5.1 5.1 2.12x10
8
 1.19x10
14
 
Lungs 4.4 4.4 1.25x10
8
 6.19x10
13
 
 
3. Results and discussion 
 
 3.1. Comparisons of S values 125 
                                                          
1
 Evaluated Nuclear Structure Data File : http://www.nndc.bnl.gov/useroutput/131i_mird.html 
4 
 
For a given radionuclide, S values depend strongly on the dimension, shape, mass and location of the 
organs. Table 3 shows the S values computed with GATE 6.1 and EGSnrc. The differences between 
GATE 6.1 and EGSnrc don’t exceed 1.5% except for thyroid and eyes. For small organs, the ranges of 
emitted electrons are not negligible compared to the dimensions of the organs and the tracking of the 
particles becomes crucial. The differences observed between the MOBY phantom and the CT scan 130 
based phantom are not representative except for thryoid and eyes. 
 
Table 3 : 
131
I S values for the MOBY phantom and the CT scan based phantom computed with GATE 6.1 and 
EGSnrc. 
Organs 
S value MOBY phantom 
(Gy.Bq
-1
.s
-1
) 
S value CT scan phantom 
(Gy.Bq
-1
.s
-1
) 
GATE 6.1 EGSnrc GATE 6.1 EGSnrc 
Melanoma 1.42x10
-10
 1.42x10
-10
 9.97x10
-11
 1.01x10
-10
 
Thyroid 2.54x10
-08
 2.61x10
-08
 4.01x10
-08
 4.15x10
-08
 
Eyes 1.41x10
-09
 1.45x10
-09
 1.55x10
-09
 1.59x10
-09
 
Liver 5.58x10
-11
 5.63x10
-11
 5.57x10
-11
 5.61x10
-11
 
Kidneys 8.45x10
-11
 8.49x10
-11
 1.45x10
-10
 1.43x10
-10
 
Lungs 1.32x10
-10
 1.34x10
-10
 1.62x10
-10
 1.67x10
-10
 
 135 
 3.2. Comparisons between digital and CT scan based dosimetries 
 
The absorbed dose computed from S values and cumulated activity computed from measurements are 
presented in Figure 1. For clinical purposes, this information is mandatory to establish the relationship 
between the injected activity of [
131
I]-ICF01012 and the inhibition of tumoral growth and metastases 140 
spread observed for mice. 
 
 
Figure 1 : Comparisons of absorbed dose to organs for the MOBY phantom and the CT scan based phantom, 
[
131
I]-ICF01012. 145 
4. Conclusion 
 
In a previous publication, we have validated GATE/GEANT4 for the transport of monoenergetic 
electrons between 50 keV and 20 MeV. Here, we have shown that in a preclinical context GATE 6.1 
(making use of the Standard Electromagnetic Package of GEANT4 9.4) is suitable for targeted 150 
radiotherapy application involving 
131
I beta emitter. GATE provides not only convivial tools but gives 
access to the versatility of GEANT4 physics. In a near future, it will be possible to extend the physics 
5 
 
range at a lower scale by using GEANT4-DNA models and processes allowing the tracking of charged 
particles at the nanometer scale. 
 155 
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